Ferriprox Tablet
FDA Label NDC 10122-104

37 label sections · Submitted to the FDA by Chiesi Usa, Inc. · Indications, Dosage, Usage, and Precautions

Structured Product Label

The following Structured Product Label (SPL) was submitted to the FDA by Chiesi Usa, Inc. for the product Ferriprox (NDC 10122-104). This document serves as the official prescribing information, containing essential scientific data and clinical materials required for healthcare providers and patients.

This specific version of the label includes detailed information regarding warning: agranulocytosis and neutropenia, 1       indications and usage, 2.1       important dosage and administration information, 2.2       recommended dosage for 1,000 mg ferriprox tablets (twice a day) for adult and pediatric patients with transfusional iron overload due to thalassemia syndromes, sickle cell disease or other anemias, 2.3       recommended dosage for 1,000 mg ferriprox tablets (three times a day) for adult and pediatric patients with transfusional iron overload due to thalassemia syndromes, sickle cell disease or other anemias, 2.4        monitoring ferritin levels to assess efficacy, 2.5      dosage modification for drug interactions, 3       dosage forms and strengths, and other regulatory disclosures. Use the navigation below to review specific sections of the FDA submission.

Label Section Quick Index

* Please review the disclaimer below.